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TO THE EDITOR
The remarkable clinical benefit of
donor-lymphocyte infusions, as well as
the finding that human T cells can
destroy chemotherapy-resistant cell
lines from chronic myeloid leukemia
and multiple myeloma, has encouraged
the development of immunotherapeutic
strategies against hematological can-
cers. Vaccination with leukemia-asso-
ciated antigen peptides might constitute
one way to induce clinical responses in
patients (Van et al., 2010). The survivin
protein is expressed in high levels in
most hematopoietic malignancies and
solid cancers (Adida et al., 2000), but is
absent in normal, differentiated tissues.
Survivin is a survival protein that has
been implicated in protection from
apoptosis and regulation of mitosis.
Thus, the attractiveness of using survi-
vin as a target for clinical intervention is
based on the fact that tumor escape by
downregulation or loss of expression
of this protein would impair sustained
tumor growth. Consequently, several
clinical trials targeting survivin with a
collection of different approaches
from small-molecule antagonists to
immunotherapy are currently under
way. With regard to the latter, sponta-
neous anti-survivin T-cell reactivity was
first described in cancer patients suffer-
ing from a wide range of cancers of
different origin, including chronic lym-
phocytic leukemia and acute myeloid
leukemia, about 10 years ago (Ander-
sen et al., 2007). When used in an oral
DNA vaccine, the survivin-directed
immune response affected both tumor
cells and tumor-associated angiogen-
esis, eradicating pulmonary metastases
without toxicity, including wound heal-
ing or fertility in preclinical studies
(Xiang et al., 2005). Furthermore,
although activated B and T cells express
survivin, it has been described that
survivin-specific cytotoxic T lympho-
cytes (CTLs) did not recognize and
kill such cells ex vivo (Schmidt et al.,
2003). These and several other precli-
nical studies justified clinical testing
to evaluate the efficacy and safety of
survivin-based vaccinations. Conse-
quently, survivin-directed immuno-
therapy was quickly moved to the
clinic, and several survivin-based vac-
cination trials are currently ongoing at
different institutes (Andersen et al.,
2007).
T-cell responses toward survivin
have almost only been studied in the
context of HLA-A2. Only very few
studies have examined additional
HLA-restricted survivin immunity
(Reker et al., 2004a, b). The set of
HLA molecules expressed in a particu-
lar person is highly individual and
allows each person to present a specific
pattern of foreign peptides to the
immune system. Nevertheless, specific
HLA class I alleles have a high degree
of sequence homology and share simi-
lar peptide-binding motifs, resulting in
the presentation of identical epitopes,
owing to which they are referred
to as HLA superfamilies (Sette and
Sidney, 1998). To date, nine major
HLA class I superfamilies have been
classified according to similar peptide-
binding motifs.
A highly interesting non-HLA-A2–
restricted survivin-derived epitope is the
HLA-A11–restricted epitope Sur53-62
(DLAQCFFCFK) (Reker et al., 2004b).
On monitoring T-cell reactivity against
survivin in a melanoma patient in com-
plete regression following IL-2–based
immunotherapy, we found persistence
of HLA-A11–restricted Sur53-62–speci-
fic T cells for more than 7 years
(Hadrup et al., 2006). This could
suggest that T-cell responses against
Abbreviations: CTL, cytotoxic T lymphocyte; MM, malignant melanoma; TILs, tumor-infiltrating
lymphocytes
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this survivin epitope might have a
clinical implication, and it demon-
strated that anti-survivin T cells might
persist in the periphery for extended
periods in the absence of clinical
manifestation of disease, as well as
autoimmunity (Hadrup et al., 2006).
The most frequent members of the HLA-
A3 superfamily, HLA-A3 and HLA-A11,
are extremely homogenous and differ
only with regard to seven amino-acid
residues, most of them along the a1 and
a2 helices. Hence, we set out to exam-
ine whether the HLA-A11–restricted
epitope was, in addition, restricted to
HLA-A3.
By using the enzyme-linked immu-
nospot IFN-g secretion assay, we ex-
amined IL-2–expanded tumor-infiltrating
lymphocytes (TILs) from five head
and neck squamous cell carcinoma
patients and three malignant melanoma
(MM) patients for the presence of speci-
fic T-cell responses against Sur 53-62
(Betts et al., 2003). Indeed, we were able
to identify Sur53-62–specific T cells
among TILs from seven patients in both
HLA-A3– and HLA-A11–positive indivi-
duals (Figure 1a). In spite of this relatively
high frequency among patients, we
only identified responses in a minority
of tested cultures. As an example,
in patient MM 2, we detected signi-
ficant responses in two of eight cul-
tures available. Figure 1b shows a
representative example of TIL alone
versus ‘‘irrelevant peptides’’ versus a
significant SUR53 response. Next, we
identified distinct populations of
CD8þ CD107aþ cells by FACS,
indicating a cytotoxic potential toward
autologous presentation of SUR53-62
among TILs (Figure 2a). We were
further able to demonstrate that such
survivin-specific TILs were indeed cy-
totoxic T lymphocytes, as they only
killed transporter associated with anti-
gen processing-deficient T2-A3 or T2-
A11 cells pulsed with the Sur53-62
peptide (Figure 2b). Interestingly, the
depicted TIL (M1 and M4) originates
from the same patient who expressed
both alleles (HLA-A3þ /A11þ ), show-
ing promiscuous SUR53-specific immune
responses even in a single individual.
Moreover, we tested the ability of a
survivin-specific TIL culture to lyse
autologous tumor cells in a standard
51Cr-release assay. Here we found a
high percentage of lysis of autologous
tumor cells and significant killing
(defined as Po0.05 by a two-tailed paired
t-test) of Sur53-62 peptide–pulsed T2-A3
cells (Figure 2c). Unfortunately, we were
not able to further confirm specific lytic
activity by W6/32 antibody–blocking
assays owing to the limited availability
of samples.
HLA-A*0301, -A*1101, -A*3103,
-A*3301, and -A*6801 alleles belong
to the A3-like superfamily, which is de-
fined by a shared preference for epi-
topes. The biological relevance of
the A3-like superfamily is revealed by the
fact that high frequencies of the A3-like
superfamily alleles are conserved in all
major ethnic groups. The inclusion of
multiple epitopes in a vaccine will
undoubtedly broaden the clinical po-
tential in several important ways: Tar-
geting different HLA molecules in a
multi-epitope vaccine will increase the
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Figure 1. IFN-c release. Analysis of IL-2–expanded tumor-infiltrating lymphocyte (TIL) functionality was
initiated by enzyme-linked immunospot (Elispot) IFN-g quantification (Andersen et al., 2001). Tests were
conducted in triplicates preferably and in duplicates depending on cell availability. (a) Identification of
SUR53-62–specific TILs among cancer patients measured by IFN-g release in Elispot. Values of spot-
forming cells (SFCs) are presented as peptide-stimulated TILs after subtraction of unstimulated TILs serving
as background values. Significant SUR53-62 responses (black circles) were identified in seven of
eight patients, ranging from 49 to 187 SFCs. Examples of nonsignificant responses (gray circles) from
TILs derived from the same fragments are shown as controls. TILs contained mainly T cells with
an equal distribution of CD8þ T cells among nonsignificant (range¼ 46–96%, mean¼ 78.9%,
SD¼19%) and significant (range¼ 15–98%, mean¼ 79.8, SD¼ 28.7) SUR53-62–responding cultures.
(b) Representative wells from a highlighted culture (patient MM 1), comparing low-background counts in
unstimulated TILs () and three known HLA-A3–restricted tumor-associated antigens (TAAs), which
did not show responses in relation to a significant SUR53-62 response. The TAAs are (1) Bcl-X(L)
165–173 (RIAAWMATY) (Andersen et al., 2005); (2) Rho1 (RAGLQVRKNK); and (3) Rho1L2
(RLGLQVRKNK) (Wenandy et al., 2008).
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number of patients eligible for immu-
notherapy and will further decrease the
risk of immune escape by class I HLA
allele loss; loss of a single class I HLA
allele is a significant component of
MHC alterations described in cancer
cells, whereas total loss of class I HLA
expression is rare. Our results suggested
that the Sur53-62 peptide corresponds
to a promiscuous cytotoxic T lympho-
cyte epitope, which is restricted to the
HLA-A3 superfamily, emphasizing its
utility for the design and development
of epitope-based anticancer immune
therapies or for immune monitoring of
vaccination trials using longer peptides
or full-length antigens.
The protocols were approved by
the Scientific Ethics Committee for
The Capital Region of Denmark and
conducted in accordance with the
provisions of the Declaration of
Helsinki. Written informed consent
from the donors was obtained before
study entry.
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Figure 2. Lytic capacity was analyzed by FACS and Cr-release assay. Tests were conducted in triplicates preferably and in duplicates depending on cell
availability. (a) Identification of CD107a-positive T-cell populations among CD8þ tumor-infiltrating lymphocytes (TILs) in two separate cultures (M4 and M6)
upon SUR53-62 stimulation in a HLA-A3þ /A11þ and a HLA-A3þ patient, respectively. Unstimulated TILs and the irrelevant peptide HIV C31 show
equal low-background staining. Stimulants were added directly into wells with TILs. (b) Further assessment by Cr-release assay showed specific killing of
SUR53-62–pulsed T2 cells restricted to either HLA-A3 or HLA-A11. TILs from M1 (97% CD8þ ) show T2-A11–restricted killing and no lysis of T2-A3 cells
presenting the SUR53-62 peptide. TILs from M4 (15% CD8þ ) from the same patient induce specific killing directed against the SUR53-62–pulsed
T2-A3þ cells. Effector:target (E:T) ratios are CD8 corrected. (c) Identification of the cytotoxic capacity of TILs (92% CD8þ ) from a HLA-A3þ patient, against
an autologous tumor cell line and T2-A3 cells presenting SUR53-62 (P¼0.01). The complete alignment of lytic activity suggests that this particular survivin-
derived epitope, presented by HLA-A3, has an impact on the reinduced immune-mediated tumor cell destruction.
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TO THE EDITOR
Primary cutaneous diffuse large B-cell
lymphoma leg type (PCDLBCL-LT) is a
unique entity (ICD-O code 9680/3)
individualized from other primary
cutaneous B-cell lymphomas (PCBCL)
and from nodal B-cell lymphomas by
three main clinical features: preferential
leg localization, occurrence in the
elderly, and poor prognosis with a
45% 5-year survival rate (Vermeer
et al., 1996; Meijer et al, 2008).
In nodal DLBCL, gene expression
profiling has identified two main signa-
tures, indicative of either germinal
center (GC) or post-germinal center–-
activated B-cell (ABC) stages of B-cell
differentiation (Alizadeh et al., 2000).
The ABC or post-GC type of DLBCL
exhibits a poor overall survival together
with a constitutive activation of the
NF-kB pathway and a higher prolifera-
tion index (Lenz and Staudt, 2010).
Interestingly, the expression profile of
PCDLBCL-LT is similar to that of the ABC
type with constitutive NF-kB pathway
activation and strong expression of the
IRF4/MUM1B-cell transcription factor,
whereas primary cutaneous follicle cen-
ter lymphoma (PCFCL), even with large
cell morphology, belongs to the GC-like
category (Hoefnagel et al., 2005; Meijer
et al, 2008). An RNA interference screen-
ing for genes implicated in proliferation
or survival of nodal B-cell lymphoma led
to identify oncogenically active MYD88
mutations in 29% of nodal ABC-type
DLBCL (Ngo et al., 2011). This prompted
us to investigate the MYD88 gene status
in PCDLBCL-LT.
According to the Declaration of
Helsinki Principles, the study was
conducted after approval from the
regional bioethics committee with in-
formed written consent from the patient.
Skin samples from 38 patients were ana-
lyzed: 16 with PCDLBCL-LT, 14 with
PCFCL, 4 with primary cutaneous
marginal-zone lymphoma (PCMZL),
and 4 with secondary cutaneous DLBCL.
For PCDLBCL-LT and secondary cuta-
neous DLBCL, the tumor cell content
was estimated above 80% on routine
sections and after immunostaining.
PCFCL and PCMZL cases were similarly
selected from surgical skin biopsies
containing tumor cell content above
20%. DNA was extracted from frozen
material in 35 cases and from formalin-
fixed material in 3 cases with the
QIAGEN DNA easy kit (QIAGEN,
Courtaboeuf, France). Constitutional
DNA was extracted from blood samples
matched to patients. Sanger sequencing
of MYD88 was accomplished with the
following primers: 50-TCCCATGGAGC
TCTGACCAC-30 and 50-TAGSAGGAGA
TGCCCAGTAT-30 (PCR amplification
and sequencing exon 3); 50-ATGCTGAA
CTAAGTTGCCACA-30 and 50-GAGGC
CCCACCTACACATTC-30 (PCR amplifi-
cation and sequencing exon 4); 50-CTG
GGGTTGAAGACTGGGCT-30 and 50-A
TGGACAGGCAGACAGATAC-30 (PCR
amplification and sequencing exon 5.
The sequence of each amplified frag-
ment was determined on both strands
with the Big Dye Terminator v1.1 ready
reaction cycle sequencing kit (Applied
Biosystems, Villebon-sur-Yvette, France).
Among 16 cases of PCDLBCL-LT
tested, a thymine to cytosine base
transition at position 794 of the com-
plementary DNA coding sequence
(c. 794 T4C), causing a L265P—leucine
to proline—amino-acid mutation, was
detected in 11 cases (69%) (Table 1).
All cases harboring the L265P mutation
appeared heterozygous, as both normal
and mutated alleles were detected at
similar levels (Figure 1). None of our
samples harbored any of the other
mutations of MYD88 identified in nodal
B-cell lymphoma cases (V217F, W218R,
S219C, I220T, S222R, M232T, S243N,
T294P) (Ngo et al., 2011). In six
PCDLBCL-LT cases for which matched
germline DNA was available, the L265P
MYD88 gene mutation was shown to be
somatically acquired (Figure 1, Table 1).
Clinical features of PCDLBCL-LT with
L265P mutation (11/16, 69%) did not
differ from those without MYD88 muta-
tion (5/16, 31%). No correlation was
found with prognosis (overall survival,
progression free survival, time to relapse
or specific death) or response to therapy
(Table 1).
The MYD88 mutation was found to
be specific for PCDLBCL-LT among
other PCBCLs. None of the 14 PCFCL
cases (three of them with large cell
morphology) and none of the 4 PCMZL
Abbreviations: ABC, activated B cell; DLBCL, diffuse large B-cell lymphoma; GC, germinal center;
PCBCL, primary cutaneous B-cell lymphoma; PCFCL, primary cutaneous follicle center lymphoma;
PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma, leg type; PCMZL, primary cutaneous
marginal zone lymphoma
2118 Journal of Investigative Dermatology (2012), Volume 132
A Pham-Ledard et al.
MYD88 Mutation in PCDLBCL, Leg Type
